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Purpose: The purpose of this study was to analyze prognosis and treatment results for seminoma arising in 
corrected and uncorrected inguinal cryptorchidism (SCIC and SUIC). 
Methods and Materials: We reviewed 66 patients with inguinal seminomas between June 1958 and December 
1991 at the Cancer Hospital and Institute of Chinese Academy of Medical Sciences. Of these patients, 23 had 
prior orchiopexy and 43 presented with an inguinal form of cryptorchidism. At presentation, 17 of 66 (26%) 
patients had nodal metastases. This nodal involvement was 30% (7 of 23) for SCIC and 23% (10 of 43) for SUIC, 
respectively. These numbers are comparable with those in a series of patients treated for scrotal seminoma at 
our institution (26% vs. 20%). However, 3 of 23 (13%) patients who had prior orchiopexy presented with 
inguinal nodal metastasis as compared with 0 of 43 patients with SUIC or 4 of 237 patients with scrotal seminoma 
(p < .05). There were 49 stage I, 5 stage IIA, 8 stage IIB, 3 stage III, and 1 stage IV patients. All patients 
underwent radical orchiectomy and received further radiotherapy, chemotherapy, or both. Patients with stage I
and stage II disease were treated primarily with radiotherapy, whereas patients with stage III and IV disease 
were treated with chemotherapy. 
Results: The overall and disease-free survival at 5 and 10 years was 94% and 92%, 89% and 87%, respectively. 
The overall 5- and lo-year survival by stage was 100% and 100% for stage I, and 77% and 68% for stage II, 
respectively @ < .05). There was no significant difference in survival between SUIC and SCIC (93% vs. 96% 
at 5 years). Four patients developed relapse. Two of these four patients experienced relapse at the inguinal area, 
due to a marginal miss. Three of four patients with relapse were successfully salvaged, and one died of disease. 
Conclusion: Our results indicate that prognosis for inguinal seminoma is excellent and similar to that of scrotal 
seminoma. Postorchiectomy radiotherapy can be considered as the standard treatment for stage I and IIA inguinal 
seminoma. We recommend routinely including the para-aortic and ipsilateral pelvic nodes. 0 1997 Elsevier 
Science Inc. 
Seminoma, Cryptorchidism, Radiotherapy. 
INTRODUCTION 
Testicular tumors account for only 1% of all malignancies, 
but are among the most common cancers in young men 
(4, 12). Moreover, it is well known that cryptorchidism 
is a risk factor in the development of germ-cell tumors (7, 
24, 25, 40). Seminomas are more common in unde- 
scended testis, with more than 80% of testicular tumors 
being histologically labeled as seminomas in abdominal 
(pelvic), more than 60% in inguinal, and 50% in normally 
descended testis ( 1,2, 14). Several studies have suggested 
that early orchiopexy reduces the risk of seminoma de- 
velopment (1, 14, 17). 
Data in the literature on inguinal seminomas are rare 
and the numbers of patients in published series are 
small. Inguinal seminoma is generally discussed under 
the topic of germ-cell tumor in cryptorchid testes or in 
combination with seminoma in abdominally unde- 
scended testis (2, 10, 20, 35). Seminoma arising in an 
undescended inguinal cryptorchid testicle is extremely 
rare in Western countries because inguinal cryptorchi- 
dism is systematically corrected ( 14, 30). In contrast to 
patients with scrotal seminoma, clinical studies report a 
high proportion of advanced stage disease in patients 
with cryptorchid seminoma. The optimal management 
after orchiectomy for cryptorchid seminoma is less well 
established and the prognosis is controversial ( 1, 2, 10, 
18, 20, 32). It remains unclear whether the poor prog- 
nosis observed in inguinal seminoma is due to advanced 
stage or other factors. In this study, we retrospectively 
reviewed our experience with inguinal seminoma, in an 
attempt to analyze clinical features, pathway of nodal 
spread, and prognosis, and also to determine the treat- 
ment option for this rare entity. 
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METHODS AND MATERIALS 
From June 1958 to December 1991, 373 patients with 
testicular seminomas were treated at the Cancer Hospital 
and Institute of Chinese Academy of Medical Sciences, 
Beijing, China. The diagnosis of pure seminoma was con- 
firmed in all cases by histopathologic review. Of these 373 
patients, 136 had a history of cryptorchidism, of whom 25 
(23 inguinal and 2 pelvic) had prior orchiopexy. Sixty- 
eight patients with seminomas arising in pelvic unde- 
scended cryptorchid testis were reported elsewhere (22). 
Of the remaining 66 patients, 43 patients had primary tu- 
mor located distally or proximally in the inguinal canal, 
and 23 patients who underwent prior orchiopexy for in- 
guinal cryptorchidism presented with primary tumor in the 
scrotum. These 66 patients, with seminoma arising in sur- 
gically corrected (n = 23) and uncorrected (n = 43) in- 
guinal cryptorchidism (SUIC and SCIC), form the basis 
of this study. The characteristics of these 66 patients were 
compared with 237 patients with seminoma arising in a 
normally descended testis. For ease of discussion the latter 
cohort of patients is labeled “scrotal seminoma.” 
Staging 
Patients were staged according to Table 1. Clinical stag- 
ing included a medical history, physical examination, 
blood chemistry, and chest X-ray. Intravenous pyelogra- 
phy (IVP) was done in 40 patients. Since 1982, computed 
tomography scans (CT) and/or ultrasound of abdomen 
and pelvis were carried out in 34 patients. Tumor markers 
including a-fetoprotein (crFP) and P-human chorionic go- 
nadotrophin (PHCG) have been determined in 35 pa- 
tients. 
Treatment 
All but four patients underwent inguinal radical or- 
chiectomy. These 4 of 23 patients with prior orchiopexy 
had a scrotal incision. Two patients had inguinal node 
dissection as well. After orchiectomy, all patients received 
postoperative radiotherapy, chemotherapy, or both. The 
treatment options were dependent on the stage of the dis- 
ease. Patients with stage I and II disease were usually 
treated with radiotherapy, whereas in patients with stage 
III and IV chemotherapy was considered the primary treat- 
ment with or without radiotherapy. As shown in Table 2, 
of 49 patients with stage I disease, 45 patients were treated 
with radiotherapy alone and 4 with chemotherapy alone. 
Among the 13 stage II patients, the primary treatment was 
radiotherapy in 7, and chemotherapy in 6. Three of the 
latter received chemotherapy only. Three patients with 
stage III and IV disease received chemotherapy with or 
without radiotherapy and only one stage III patient re- 
ceived radiotherapy alone. 
Radiotherapy was initially given with a Cobalt-60 unit 
and, after 1982, with an 8-MV linear accelerator. Daily 
dose varied from 150 to 200 cGy. Patients with stage I 
and IIA disease had their para-aortic nodes irradiated with 
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Supradiaphragmatic node metastases 
Extralymphatic metastases 
parallel opposed anterior-posterior (AP-PA) fields. The 
ipsilateral pelvic nodes were routinely treated. Before 
1987, the treatment for pelvic nodes was delivered 
through a single anterior field. In most cases, this field 
included the medial and upper inguinal nodes, as previ- 
ously described (3 I). After 1987, parallel opposed fields 
(dog-leg) were used and inguinal nodes were excluded in 
the treatment volume. The infradiaphragmatic dose for 
stage I and IIA disease ranged from 15 to 40 Gy with a 
median of 30 Gy. Of the six stage IIB patients receiving 
radiotherapy, four were treated with a para-aortic and ip- 
silateral pelvic field similar to stage I patients, but the 
treatment portals were tailored to cover the bulky abdom- 
inal disease. Two stage IIB patients were treated with ei- 
ther whole abdominal-pelvic irradiation (WAPI) or lo- 
cal-field radiotherapy following chemotherapy. In contrast 
to stage I, higher total doses (median 35 Gy) were applied 
to stage IIB patients. Of the two stage III patients who 
received radiotherapy, one was treated with para-aortic, 
pelvic, and mediastinal irradiation, and one with WAPI 
following chemotherapy. One stage IV patient was treated 
with combination chemotherapy followed by whole lung 
irradiation. 
Seven patients received the ipsilateral inguinal irradia- 
tion and one patient with bilateral inguinal invasion re- 
ceived elective irradiation to the bilateral inguinal and pel- 
vic nodes. Ipsilateral hemiscrotum was irradiated in only 
four cases of scrotal incision. Prophylactic mediastinal and 
left supraclavicular irradiation was given to 2 of 13 pa- 
tients with stage II disease. 
Thirteen patients were treated with chemotherapy (Ta- 
ble 2). Eight of these patients were treated with chemo- 
therapy alone and five with a combination of chemother- 
apy and radiotherapy. Before 1985, chemotherapy 
Table 2. Radiotherapy and chemotherapy according to stage 
Stage 
I IIA IIB III IV Total 
RT alone 45 3 4 1 0 53 
Chemo alone 4 1 2 I 0 8 
Chemo + RT 0 1 2 1 1 5 
RT = radiotherapy; chemo = chemotherapy. 
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consisted of N-formylsarcolycin at 30 mg/day orally for 
1-2 months (8 patients). Thereafter, a combination reg- 
imen of cisplatin. vinblastine, and bleomycin (PVB ) was 
applied to the five patients. 
Follow-up and statistics 
Patients were followed every 3 months for 1 year, and 
thereafter every 6 months or once yearly. At each follow- 
up, they were submitted to physical examination, com- 
plete blood count, serum biochemistry, and chest X-rays. 
Abdominal-pelvic CT scan and/or ultrasound were per- 
formed since 1982. 
The follow-up time ranged from 3 to 34 years with a 
median of 12 years. The overall survival was calculated 
from the date of surgery. Disease-free survival was cal- 
culated from the date of surgery until evidence of recur- 
rence or progression. Updating of the medical files was 
done in December 1994 and survival data were calculated 
according to these. Survival curves were calculated by the 
Kaplan-Meier product-limit method ( 19) and differences 
between survival curves were analyzed with the log rank 
test (29). Numerical data were compared with Student’s 
t-test and qualitative data with the Chi-square test or 
Fisher’s exact test. 
RESULTS 
Patient characteristics 
Patient ages varied from 18 to 58 years with a median 
of 32 years. Most patients (46 of 66, 70%) were between 
30 and 50 years of age. There were 30 right and 36 left 
primary sites. Fourteen of 66 (2 1% ) patients had a history 
of contralateral cryptorchidism. Correction of an ipsilat- 
era1 inguinal hernia was performed in seven patients. Ob- 
vious invasion of the surrounding soft tissue was observed 
in three cases. The most frequently encountered symptom 
at presentation was an inguinal or scrotal mass, which was 
painful in 16 patients. Clinical characteristics are sum- 
marized in Table 3. 
The size of the primary tumor arising in an inguinal 
testes ranged from 3 to 12 cm, with mean and median sizes 
of 6.5 cm and 7 cm, respectively. These are similar to data 
of scrotal seminoma (range 2- 15 cm, median 6 cm). 
Seventeen of 66 (26%) patients with inguinal semi- 
noma had lymph node metastases. Patients with SCtC had 
a 30% (7 of 23) incidence of nodal metastases, not sig- 
nificantly different from the 23% (10 of 43) incidence 
encountered in SUIC. In Table 4, the stage distribution of 
inguinal seminoma has been compared with that of scrotal 
seminoma. Again, there was no significant difference in 
nodal involvement between the two groups (20% for scro- 
tal vs. 26% for inguinal seminoma) . 
Fourteen of 17 patients with nodal disease had para- 
aortic involvement without pelvic or inguinal node me- 
tastases. However, three patients with SCIC had inguinal 
nodal metastases without pelvic or para-aortic node in- 
volvement. Two of these three patients with inguinal nodal 
involvement experienced this condition unilaterally, 
whereas the third presented with bilateral nodal involve- 
ment. However, none of the patients with SUIC showed 
an inguinal nodal presentation. The difference in inci- 
dence of inguinal involvement between SCIC (3 of 7, 
43%) and SUIC (0 of 10) is significant, as is the differ- 
ence between SCIC and scrotal seminoma (4 of 48, 8%). 
Table 4. Stage distribution of inguinal seminoma compared with that of scrotal seminoma 
Stage 
I II 111 IV 
No. (%I No. (%) No. (%) No. (%I 
SUIC 33 (77) 8 (19) 1 (2) 1 (21 
SCIC 16 (70) 5 (22) 2 (9) 0 (0) 
Scrotal 189 (80) 29 (12) 5 (2) 14 (6) 
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Survival 
Five patients died of inguinal seminoma, and one of a 
cerebrovascular accident. The overall 5- and lo-year sur- 
vival for all 66 patients was 94% and 92%, respectively. 
The corresponding disease-free survival was 89% and 
87% (Fig. 1). The overall 5- and IO-year survival by stage 
was 100% and 100% for stage I, and 77% and 68% for 
stage II, respectively (Fig. 2). The difference in survival 
between stage I and II was statistically significant (p < 
.05). All five stage IIA patients were alive with no evi- 
dence of disease, whereas 4 of 8 stage IIB patients died 
of disease. We treated only four patients with stage III and 
IV disease and one stage III patient who received radio- 
therapy alone died of progression. Due to the small num- 
ber of patients, no actuarial survival was calculated for the 
latter groups. For 43 patients with SUIC, the overall and 
disease-free survival at 5 and 10 years was 93% and 90%, 
and 88% and 85%, respectively. The overall and disease- 
free survival for 23 patients with SCIC at 5 years was 96% 
and 91%, respectively. No significant difference in sur- 
vival was observed between SUIC and SCIC. 
Recurrence 
Four patients relapsed at 8, 13, 18, and 42 months after 
initial therapy. One stage I patient who was initially 
treated with N-formylsarcolycin developed abdominal re- 
currence. He was salvaged with radiotherapy and is still 
alive 26 years after salvage treatment. One stage IIB pa- 
tient developed liver metastases and died of progressive 
disease. Two patients who received infradiaphragmatic ra- 
diation experienced relapse at the ipsilateral inguinal 
node. One patient had pelvic relapse as well. One patient 
presented with stage II SUIC and one with stage 1 SCIC. 
Both patients were initially treated with a single anterior 
pelvic field. Therefore, this site of recurrence can be con- 
sidered as a geographic miss. They were salvaged with 
radiotherapy. However, one of these patients developed a 
second relapse in the pelvis. The iatter patient underwent 
pelvic and inguinal node dissection, and was finally suc- 
cessfully salvaged with a PVB combination. 
Complications 
Long-term complications were observed in two pa- 
tients. There was one case of radiation-related hemor- 
rhagic cystitis. This patient presented with stage I disease 
and received 35 Gy at the midline level to the para-aortic 
and ipsilateral iliac areas. The pelvic area was irradiated 
by a single anterior field given with a Cobalt-60 unit. The 
estimated irradiation dose to the bladder was 41-45 Gy. 
He presented with hemorrhagic cystitis 43 months after 
irradiation, confirmed by endoscopy. The other patient, 
retreated for inguinal recurrence by radiotherapy, devel- 
oped an ipsilateral leg edema and muscular atrophy. The 
cumulative dose reached 90 Gy to the pelvis and inguinal 
area. Both patients are still alive without evidence of dis- 
ease. 
Three patients had a second malignant tumor. Two pa- 
tients had synchronous contralateral scrotal seminoma. 
One patient with stage I inguinal seminoma developed a 
contralateral testicular mixed tumor (seminoma plus ter- 
atoma) 6 years after radiotherapy. 
DISCUSSION 
Presentation 
In the current study, we retrospectively reviewed 66 
patients with inguinal seminoma. Forty-three of these pa- 
tients had primary tumor in the inguinal area, and 23 had 
prior orchiopexy and thus they presented with their pri- 
mary tumor in the scrotum. Inguinal seminoma is appar- 
ently more common in China than in Western countries 
( 10, 35, 36). The age peak, chief complaint, presenting 
signs, and symptoms are comparable with seminoma in 
normally descended testes. In accordance with other series 
(10, 13, 32), we found 21% bilateral cryptorchidism in 
patients with inguinal seminoma and 19% in patients with 
pelvic cryptorchid seminoma. 
The size of primary tumor in inguinal seminoma is sim- 
ilar to that found in scrotal seminoma, but it is much 
smaller than that seen in pelvic cryptorchid seminoma 
(22). This can easily be explained by early detection and 
diagnosis of tumor development in case of inguinal and 
scrotal seminoma. 
Lymphatic metastases 
The incidence of lymphatic metastases in the present 
series is consistent with that observed by Shi et al. ( 17%) 
(36). Gauwitz et al. (10) confirms this observation and 
reports a 33% (3 of 9) incidence in SUIC, not significantly 
different from the 25% incidence observed in scrotal sem- 
inoma, but significantly lower than in patients with pelvic 
cryptorchid seminoma (76%, 13 of 17 ) . These data, how- 
ever, are in contrast with most other published reports on 
nodal metastases in cryptorchid seminoma ( 1, 2, 20, 32). 
However, the latter reports contain a smaller number of 
patients as compared with the former. 
As it is the case in scrotal seminoma, the nodal spread 
in patients with inguinal seminoma is primarily to the 
para-aortic nodes. However, we more frequently found 
inguinal nodal involvement in patients with SCIC as com- 
pared with SUIC or scrotal seminoma. This observation 
is consistent with the hypothesis that prior orchiopexy or 
any previous inguinal surgery disrupts the normal lym- 
phatic drainage (26,40). Therefore, those patients should 
routinely have the pelvis and inguinal regions examined. 
Prognosis and treatment 
The prognosis of inguinal and pelvic seminoma is not 
well established and conflicting results have been reported 
(Table 5 ) . Because of the rarity of this disease, the sur- 
vival of inguinal seminoma as an entity has not been an- 
alyzed extensively in the literature. The reported survival 
rates of patients with seminoma in cryptorchid testis have 
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Table 5. Summary of the relationship between stage and survival in the literature 
Stage 
Stage 1 Stage II III/IV 
Investigators and year Years of Number of 
(reference number) treatment Diagnosis patients No. (%) No. (%) No. (%) Five-year survival 
Abratt et al. 1992 (1) 1970- 1991 cs 20 11 (55) 4 (20) 5 (25) 76% for all patients; 
100% for 13 
stage I and IIA 
Batata ef al. 1980 (2) 1934- 1975 cs 54 33 (61) 14 (26) 7 (13) 78% for all patients; 
97% for stage I 
Gauwitz and Zagars 1992 (10) 1960-1990 PCS 17 4 (24) 11 (65) 2 (12) 92% for all patients 
SUIC 9 6 (67) 3 (33) 0 (0) 
Sham et al. 1990 (35) 1972-1986 PCSlSUIC 9 6 (67) 2 (22) 1 (11) 6 stage I patients 
alive at 2 years 
Kulkami and I&mat 1991 (20) 1980- 1986 PCSWJIC 12 4 (33) 6 (50) 2 (17) 100% for 8 stage I 
and nonbulky II 
Shi et al. 1987 (36) 1960-1980 PCS 39 27 (69) 11 (28) 1 (3) 89% for all patients; 
SUIC 64 53 (83) 7 (11) 4 (6) 97% for stage I 
Li et al. (current series) 1958- 1991 PCS 60 34 (57) 17 (28) 9 (15) 92% for PCS; 
100% and 94% 
for stage I and II, 
resp. 
1958 1991 SUIC 43 33 (77) 8 (19) 2 (4) 93% for SUIC 
SCIC 23 16 (70) 5 (22) 2 (9) 96% for SCIC; 
100% for stage I 
CS: cryptorchid seminoma, including all seminomas in corrected and uncorrected pelvic/inguinal testis; PCS: pelvic cryptorchid 
seminoma, seminoma in uncorrected abdominal/pelvic testis; SUIC: seminoma in uncorrected inguinal cryptochidism; SCIC: seminoma 
in corrected inguinal cryptorchidism. 
been reported to range from 76% to 92% at 5 years ( 1, 2, 
10,36). However, more detailed analyses of survival data, 
including ours, show that early stage disease in cryptor- 
chid seminoma carries an excellent prognosis with 97- 
100% 5year survival after radiation therapy (1, 2, 20, 
36)) which is in accordance with those obtained for scrotal 
seminoma(3, 11, 15,37,38,41).Thelowlevelofoverall 
survival in most series is mainly explained by the poor 
results in more advanced-stage disease, due particularly 
to the lack of an effective chemotherapy combination in 
previous years. 
For stage I patients primarily treated with radiotherapy 
the selection of an optimal treatment volume is an impor- 
tant consideration. Based on our experience, we recom- 
mend treating the para-aortic and ipsilateral iliac nodes for 
patients with SUIC or SCIC. Radiation dose should not 
exceed a total of 25-30 Gy. There is no convincing evi- 
dence for treating the inguinal lymph nodes and the tumor 
Disease-free survival 
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Fig. 1. Overall and disease-free survival for 65 patients with inguinal seminoma. 
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bed in patients with seminoma in undescended inguinal 
testis, because the para-aortic lymph nodes remain the first 
pathway and the rate of inguinal soft tissue invasion is 
very low. As stated by other investigators, the inguinal 
lymph nodes should be routinely treated only in those pa- 
tients who had prior inguinal or scrotal surgery, because 
of their high risk of nodal involvement (3, 37, 39,41) . In 
the present series, of 14 stage I patients with SCIC treated 
with radiotherapy, 9 patients received partial inguinal ir- 
radiation by a single anterior pelvic field (before 1987) 
and only one patient received complete inguinal irradia- 
tion. As a general rule, inguihal and scrotal radiation 
should be avoided whenever possible. The scattered dose 
to the remaining testis contributes to a higher risk of in- 
fertility and perhaps to a second testicular cancer as well. 
No patient in the present series had scrotal relapse, sug- 
gesting that the use of scrotal irradiation may not be nec- 
essary except in instances of overt tumor involvement of 
scrotal tissues. Regarding the uncertainty of lymph drain- 
age after corrective surgery in SCIC, adjuvant chemo- 
therapy may be an effective alternative in these patients 
(8, 28). 
Patients with stage IIA disease should receive irradia- 
tion to the para-aortic and ipsilateral pelvis. However, if 
the inguinal nodes or inguinal surrounding soft tissues (tu- 
mor bed) are involved, then the ipsilateral inguinal nodes 
and the tumor bed should be treated. 
Despite the fact that only two patients received prophy- 
lactic mediastinal irradiation, no relapse episodes were 
found in the mediastinal and supraclavicular regions in 
stage II patients. As is the case with scrotal seminoma (3, 
6, 2 1, 34, 39)) prophylactic mediastinal irradiation for in- 
guinal seminoma has been abandoned. 
Combination chemotherapy, especially platinum-based 
regimens, which are currently used for bulky stage II scro- 
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tal seminoma (5,27,41> , are recommended for stage IIB 
inguinal seminoma. 
No definite conclusions can be made concerning stage 
III and IV inguinal seminoma because of the small number 
of patients. However, there is no reason to believe that the 
treatment of choice for stage III and IV inguinal semi- 
noma, that is, combined platinum-based chemotherapy, 
should be different than in the case of scrotal seminoma 
at the same stage (8, 9, 23). 
Complication 
Late complications can be avoided by carefully select- 
ing adequate techniques. The unique case of hemorrhagic 
cystitis was observed in a patient with a 35Gy dose ( spec- 
ified at the midline). This untoward effect on the bladder 
at this low dose level can be explained by the use of an 
inappropriate technique in previous years. In this partic- 
ular patient, the target volume was treated by a single an- 
terior field given with a Cobalt-60 unit. This implies that 
there was at least a 20-30% dose heterogeneity in the 
treated volume, and a large fraction size on the anterior 
port to the bladder, resulting in the late complication. 
Proper field arrangement and definition of target volumes 
are prerequisites for tumor cure, and, in case of relapse 
after radiotherapy, as was shown in this and many other 
series, combined chemotherapy should be considered for 
salvage therapy. 
CONCLUSION 
Seminoma arising in uncorrected or corrected inguinal 
cryptorchid testis is an uncommon clinical problem, but a 
higher incidence of this tumor was observed in China. The 
frequency of nodal involvement and its spread are similar 
to that of scrotal seminoma. Inguinal nodes in patients 
Stage I 
Stage II 
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Fig. 2. Overall survival by stage in inguinal seminaoma: stage I (n = 49) and stage II (n = 13). 
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with prior orchiopexy (SCIC) are more frequently ob- be included in the treatment ports only when they are in- 
served than in patients with noncryptorchid seminoma or volved or if there is obvious involvement of surrounding 
seminoma arising in uncorrected inguinal testes. In early- tissues by the primary tumor. In more advanced-stage dis- 
stage disease (stage IA and IIA ) , postorchiectomy radio- ease, the treatment of choice remains combination che- 
therapy should be performed, and should include para- motherapy. Provided that the treatment is adequate, the 
aortic and ipsilateral pelvic nodes. Inguinal nodes should prognosis is excellent and stage-dependent. 
REFERENCES 
1. Abratt, R. P.; Reddi. V. B.: Sarembock, L. A. Testicular 
cancer and cryptorchidism. Br. J. Urol. 70:656-659; 1992. 
2. Batata, M. A.; Chu, F. C. H.; Hilaris, B. S.; Whitmore, 
W. F.; Golbey, R. B. Testicular cancer in cryptorchids. Can- 
cer 49:1023-1080; 1982. 
3. Bayens, Y. C.: Helle. P. A.; Van Putten. W. L. J.; Mali, 
S. P. M. Orchidectomy followed by radiotherapy in 176 
stage I and II testicular seminoma patients: Benefits of a 
IO-year follow-up study. Radiother. Oncol. 25:97-102; 
1992. 
4. Boyle, P.; Kaye, B. S.: Robertson. A. G. Changes in testic- 
ular cancer in Scotland. Eur. J. Cancer Clin. Oncol. 23:827- 
830; 1987. 
5. Dosmann, M. A.: Zagars. G. K. Postorchiectomy radiother- 
apy for stages I and II testicular seminoma. Int. J. Radiat. 
Oncol. Biol. Phys. 26:381-390; 1993. 
6. Evensen, J. R.; Fossa. S. D.; Kjellevold, K.; Lien, H. H. 
Testicular seminoma: Analysis of treatment and failure for 
stage II disease. Radiother. Oncol. 4:55-61; 1985. 
7. Farrer, J. H.; Walker, A. H.; Rajfer, J. Management of the 
postpubertal cryptorchid testis: A statistical review. J. Urol. 
134:1071-1076; 1985. 
8. Fossa, S. D.; Droz, J. P.: Stoter, G.; Kaye, S. B.; Vermey- 
len, K.; Sylvester, R. Cisplatin, vincristine and ifospham- 
ide combination chemotherapy of metastatic seminoma: 
Results of EORTC trial 30874. Br. J. Cancer 71:619-624; 
1995. 
9. Friedman. E. L.: Garnick, M. B.; Stomper, P. C.; Mauch, 
P. M.; Harington, D. P.; Richie, J. P. Therapeutic guidelines 
and results in advanced seminoma. J. Clin. Oncol. 3: 1325- 
1332; 198.5. 
10. Gauwitz, M. D.: Zagars, G. K. Treatment of seminoma aris- 
ing in cryptorchid testes. Int. J. Radiat. Oncol. Biol. Phys. 
24:153-159; 1992. 
11. Giacchetti. S.; Raoul, Y.; Wibault, P.: Droz. J. P.; Court, B.; 
Eschwege, F. Treatment of stage I testis seminoma by radio- 
therapy: Long-term results-a 30-year experience. Int. J. Ra- 
diat. Oncol. Biol. Phys. 27:3-9; 1993. 
12. Gilliland, F. D.; Key, C. R. Male genital cancers. Cancer 
75:295-315; 1995. 
13. Gross, R. E.; Jewett, T. C. Surgical experiences from 
1222 operations for undescended testes. JAMA 160:634; 
1956. 
14. Halme. A.; Kellokumpu-Lehtinen, P.: Lehtonen. T.; Teppo, 
L. Morphology of testicular germ cell tumours in treated and 
untreated cryptorchidism. Br. J. Urol. 64:78-83; 1989. 
15. Hanks. G. E.; Peters, T.; Owen, J. Seminoma of the testis: 
Long term beneficial and deleterious results of radiation. Int. 
J. Radiat. Oncol. Biol. Phys. 24:913-919; 1992. 
16. Horwich, A.; Dearnaley, D. P.; Duchesne, G. M.; Williams, 
M.: Brada, M.; Peckham. M. J. Simple nontoxic treatment 
of advanced metastatic seminoma with carboplatin. J. Clin. 
Oncol. 7: 1150- 1156: 1989. 
17. Jones. B. J.: Thornhill. J. A.; O’Donnell, B.; Kelly, D. G.; 
Walsh, A.: Fennelly. J. J.; Fitzpatrick, J. M. Influence of 
prior orchiopexy on stage and prognosis of testicular cancer. 
Eur. Ural. 19:201-203; 1991. 
18. Jonsson, K.; Wallace, S.; Jing, B. S.; Boyle, L. E.; John- 
son, D. E. Lymphangiography in patients with malig- 
nancy in anon-descended testicle. J. Urol. 119:614-617: 
197s. 
19. Kaplan, E. L.; Meier, P. Nonparametric estimation from in- 
complete observations. J. Am. Stat. Assoc. 53:457-481; 
1958. 
10. Kulkarni. J. N.; Kamat, M. R. Tumors in undescended testis. 
J. Surg. Oncol. 46:257-260: 1991. 
21. Laukkanen, E. L.; Olivotto, I.; Jackson, S. Management of 
seminoma with bulky abdominal disease. Int. J. Radiat. On- 
col. Biol. Phys. 14:227-233; 1988. 
22. Li, Y. X.; Coucke, P. A.; Qian, T. N.; Huang, Y. R.; Gu, 
D. Z.; Mirimanoff, R. 0.; Yu, Z. H. Clinical characteristic, 
prognosis and treatment for pelvic cryptorchid seminoma 
Int. J. Radiat. Oncol. Biol. Phys. (in press). 
23. Loehrer, P. J.; Birch, R.; Williams, S. D.: Greco. F. A.; Ein- 
horn, L. H. Chemotherapy of metastatic seminoma: The 
Southeastern Cancer Study Group experience. J. Clin. Oncol. 
5:1212-1220; 1987. 
24. Martin, D. C. Malignancy in the cryptorchid testis. Urol. 
Clin. North. Am. 9:371-376; 1982. 
25. Martin, D. C.; Menck, H. R. The undescended testis: Man- 
agement after puberty. J. Ural. 114:77-79; 1975. 
26. Mason, M. D.; Featherstone. T.; Olliff, J.; Horwich. A. In- 
guinal and iliac lymph node involvement in germ cell tum- 
ours of the testis: Implications for radiological investigation 
and for therapy. Clin. Oncol. 3: 147- 150; 1991. 
27. Mason, B. R.: Kearsley. J. H. Radiotherapy for stage II tes- 
ticular seminoma: The prognostic influence of tumor bulk. 
J. Clin. Oncol. 6: 1856- 1862; 1988. 
28. Oliver, R. T. D.; Edmonds, P. M.; Ong, J. Y. H.; Ostrowski, 
M. J.; Jackson, A. W.; Baille-Johnson, H.; Williams. M. V.; 
Wiltshire, C. R.; Mott. T.; Pratt, W. R.; Trask, C. W. L.; 
Hope-Stone, H. F. Pilot studies of 2 and 1 course carboplatin 
as adjuvant for stage I seminoma: Should it be tested in a 
randomized trial against radiotherapy? Int. J. Radiat. Oncol. 
Biol. Phys. 29:3-8; 1994. 
29. Peto, R.; Pike, M. C.; Armitage, P.; Breslow. N. E.; Cox. 
D. R.; Howard, S. V.; Mantel, N.; McPherson, K.; Peto, 
J.; Smith, P. G. Design and analysis of randomized clin- 
ical trials requiring prolonged observation of each patient. 
Part II. analysis and examples. Br. J. Cancer 35:1-39; 
1977. 
30. Pike. M. C.; Chilvers, C.; Peckham, M. J. Effect of age at 
orchidopexy on risk of testicular cancer. Lancet 1: 1246- 
1248; 1986. 
31. Qian, T. N.; Hu. Y. H.; Chen, C. X.; Qi. Y. Q.; Gu, D. Z.; 
Gu, X. Z. Radiation therapy of seminoma of the testis. Int. 
J. Radiat. Oncol. Biol. Phys. 7:717-720: 1981, 
32. Raina, V.: Shukla. N. K.; Gupta, N. P.; Deo, S.; Rath. G. K. 
Germ cell tumours in uncorrected cryptorchid testis at Insti- 
tute Rotary Cancer Hospital. New Delhi. Br. J. Cancer 
71:380-382; 1995. 
33. Raja, M. A.; Oliber, R. T. D.; Badenoch. 5.: Blandy, J. P. 
Orchidopexy and transformation of seminoma to non-semi- 
noma. Lancet 339:930: 1992. 
350 I. J. Radiation Oncology l Biology l Physics Volume 38, Number 2, 1997 
34. Sagerman, R. H.; Kotlove, D. J.; Regine, W. F.; Chung, 
C. T.; King, Cl. A. Stage II seminoma: Results of postor- 
chiectomy irradiation. Radiol. 172565-568; 1989. 
35. Sham, J. S. T.; Choy, D.; Chan, K. W.; Choi, P. H. K. Sem- 
inoma of normally-descended and cryptorchid testis. Eur. J. 
Surg. Oncol. 16:33-36; 1990. 
36. Shi, X. H.; Liu, T. F. Radiotherapy for seminoma arising in 
undescended testis: Analysis of 103 cases. Tumor 7:113- 
115; 1987 (in Chinese). 
37. Vallis, K. A.; Howard, G. C. W.; Duncan, W.; Combleet, 
M. A.; Kerr, G. R. Radiotherapy for stages I and II testicular 
seminoma: Results and morbidity in 238 patients. Br. J. Ra- 
diol. 68:400-405; 1995. 
38. Warde, P.; Gospodarowicz, M. K.; Panzarella, T.; Catton, 
C. N.; Sturgeon, J. F. G.; Moore, M.; Goodman, P.; Jewett, 
M. A. S. Stage I testicular seminoma: Results of adjuvant ir- 
radiation and surveillance. J. Clin. Oncol. 13:2255-2262; 1995. 
39. Willan, B. D.; McGowan, D. G. Seminoma of the testis: A 
22-year experience with radiation therapy. Int. J. Radiat. On- 
col. Biol. Phys. 11:1769-1775; 1985. 
40. Wobbes, T.; Schraffordt, K. H.; Oldhoff, J. The relation be- 
tween testicular tumours, undescended testes, and inguinal 
hernias. J. Surg. Oncol. 14:45-51; 1980. 
41. Zagars, G. K.; Babaian, R. J. Stage I testicular seminoma: 
Rationale for postorchiectomy radiation therapy. Int. J. Ra- 
diat. Oncol. Biol. Phys. 13:155-162; 1987. 
